Literature DB >> 20673710

Fatty acid metabolism in cystic fibrosis.

Birgitta Strandvik1.   

Abstract

Despite identification twenty years ago of the gene responsible for cystic fibrosis transmembrane conductance regulator (CFTR), the protein defective in cystic fibrosis (CF), research of this monogenetic disease has not provided an explanation for the divergent symptoms, and a treatment breakthrough is still awaited. This review discusses different aspects of disturbances in lipid metabolism seen in CF. These include increased release of arachidonic acid (AA) from cell membrane phospholipids and a low status of linoleic and docosahexaenoic acids. Recent research has explored more complicated lipid associations. Disturbances in annexins and ceramides might act in concert to explain the impact on inflammation and AA release. The connections to CFTR and between the disturbances in essential fatty acid metabolism are reviewed. The metabolic interactions, some of which might be compensating, possibly explain the difficulties in understanding the fatty acid disturbances in relation to different symptoms and their relation to the defective CFTR. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673710     DOI: 10.1016/j.plefa.2010.07.002

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  26 in total

1.  Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase.

Authors:  Obi C Umunakwe; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2014-05-24       Impact factor: 5.922

2.  Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.

Authors:  Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2019-12-20       Impact factor: 5.482

3.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

Review 4.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

Review 5.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

6.  Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis.

Authors:  Kelly F Thomsen; Michael Laposata; Sarah W Njoroge; Obi C Umunakwe; Waddah Katrangi; Adam C Seegmiller
Journal:  Lipids       Date:  2011-05-05       Impact factor: 1.880

7.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity.

Authors:  Sarah W Njoroge; Michael Laposata; Waddah Katrangi; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2011-11-16       Impact factor: 5.922

8.  Intestinal smooth muscle dysfunction develops postnatally in cystic fibrosis mice.

Authors:  Robert C De Lisle; Lauren Meldi; Racquel Mueller
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-12       Impact factor: 2.839

9.  Interactions of linoleic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis.

Authors:  Waddah Katrangi; Joshua Lawrenz; Adam C Seegmiller; Michael Laposata
Journal:  Lipids       Date:  2013-02-27       Impact factor: 1.880

10.  Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.

Authors:  Jun Yang; Jason P Eiserich; Carroll E Cross; Brian M Morrissey; Bruce D Hammock
Journal:  Free Radic Biol Med       Date:  2012-05-08       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.